Aclaris Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.



Total Raised


Date of IPO


Market Cap


Stock Price


About Aclaris Therapeutics

Aclaris Therapeutics is a specialty pharmaceutical dermatology company focused on the development of dermatologic therapies. The company focuses on identifying, developing, and commercializing topical dermatological technologies that fill unmet medical needs. The lead product in the Aclaris product portfolio (A-101) is currently a pre-IND asset that is being developed as a topical treatment for both medical and aesthetic indications.

Aclaris Therapeutics Headquarter Location

640 Lee Rd Suite 200

Wayne, Pennsylvania, 19087,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Aclaris Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Aclaris Therapeutics in 1 CB Insights research brief, most recently on Oct 29, 2021.

Expert Collections containing Aclaris Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aclaris Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Aclaris Therapeutics Patents

Aclaris Therapeutics has filed 23 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Dermal and subcutaneous growths
  • Immune system
patents chart

Application Date

Grant Date


Related Topics




Racing car classes, Sports car racing, Inflammations, Rally cars, Touring car racing


Application Date


Grant Date



Related Topics

Racing car classes, Sports car racing, Inflammations, Rally cars, Touring car racing



Latest Aclaris Therapeutics News

Aclaris Therapeutics Q1 2022 Earnings Preview

May 9, 2022

May 09, 2022 1:49 PM ETBy: Dania Nadeem , SA News Editor Aclaris Therapeutics ( ACRS ) is scheduled to announce Q1 earnings results on Tuesday, May 10th, before market open. The consensus EPS Estimate is -$0.41 and the consensus Revenue Estimate is $1.67M (-6.2% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 0 upward revisions and 2 downward. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Aclaris Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aclaris Therapeutics Rank

  • Where is Aclaris Therapeutics's headquarters?

    Aclaris Therapeutics's headquarters is located at 640 Lee Rd, Wayne.

  • What is Aclaris Therapeutics's latest funding round?

    Aclaris Therapeutics's latest funding round is IPO.

  • How much did Aclaris Therapeutics raise?

    Aclaris Therapeutics raised a total of $82M.

  • Who are the investors of Aclaris Therapeutics?

    Investors of Aclaris Therapeutics include Kenexa.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.